研究目的
This study aimed to retrospectively evaluate the efficacy and safety of a 1927 nm fractional Thulium fiber laser for the treatment of melasma.
研究成果
Results of this study indicate that the 1927 nm fractional Thulium fiber laser is a safe and effective treatment option for melasma. Further prospective, randomized, and controlled studies are needed to optimize the treatment parameters and to further evaluate the efficacy and safety of the 1927 nm fractional Thulium fiber laser for melasma.
研究不足
The study has a small sample size, and therefore these results need to be validated in bigger sample population studies. The follow-up period is 6 months, and the rates of recurrence of melasma or the incidence of PIH may increase during longer follow-up periods.
1:Experimental Design and Method Selection:
Retrospective evaluation of patients treated with a 1927 nm fractional Thulium fiber laser. The MASI score was used to assess improvements of the lesions.
2:Sample Selection and Data Sources:
Patients admitted to the dermatology outpatient clinic between September 2015 and March
3:List of Experimental Equipment and Materials:
20 1927 nm wavelength fractionated thulium fiber laser (LavieenBnA?, Wontech, South Korea), topical lidocaine & prilocaine cream (EMLA? 5% cream, Astra Zeneca, AB, Sweden).
4:Experimental Procedures and Operational Workflow:
Patients received two treatment sessions at one month intervals. The treatment was performed using 3 passes of a 9–10 mJ/shot with a 23 × 23 mm squared tip, which gave 30–50% surface area coverage.
5:Data Analysis Methods:
Statistical analyzes were performed using the IBM SPSS 22.0 program. Mean, standard deviation, median, and the lowest/highest, frequency, and ratio values were used to express descriptive values.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容